Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA
PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...
Phase 2b
Advertisement
Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
Glycomine Gains FDA Breakthrough Status for GLM101
San Carlos, California, U.S., September 24, 2026 Glycomine, Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Evommune to Present EVO301 Phase 2a Data at EADV 2026
PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...
Advertisements
Marea Therapeutics and Lisata to Present MAR001 Phase 2b Data
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. — September 24, 2026 Marea Therapeutics, a subsidiary of Lisata Therapeutics,...
Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
Vertex Reports Positive Inaxaplin Results in Kidney Disease
Boston, Massachusetts, U.S., September 22, 2026 Vertex Pharmaceuticals Incorporated has announced positive results from the Phase 2b AMPLIFIED study...
Lisata Acquires Marea in $225M Cardioendocrine Deal
LIBERTY CORNER, N.J. — September 17, 2026 Lisata Therapeutics announced the acquisition of Marea Therapeutics, combining the companies to...
Longeveron Reports ELPIS II Results for Laromestrocel
MIAMI — September 16, 2026 Longeveron Inc. announced topline results from its Phase 2b ELPIS II clinical trial evaluating...
Advertisement
